Latest uncovered stories

The Food and Agriculture Organization has released a regional assessment of mycotoxin contamination in Near East and North Africa food systems, identifying gaps in surveillance, laboratories and regulations. The report proposes five priority actions to strengthen prevention, detection and management. Findings were shared at a Codex side event amid climate-driven risks to staple crops.

Why uncovered:Covered by FAO primary sources and specialist food-safety outlets such as Cibum; limited pickup in mainstream international media.

A study from Rutgers School of Dental Medicine published in PNAS Nexus shows that bacteria can corrode titanium dental implants, releasing microscopic particles that disrupt macrophages. These particles, coated with bacterial toxins, trap immune cells in inflammation, reduce bacterial clearance, and contribute to peri-implantitis and jawbone loss in 10-20% of patients. The work identifies the TRPC1 calcium channel as a potential drug target.

Why uncovered:Covered by science outlets including EurekAlert, ScienceDaily and SciTechDaily, with limited pickup beyond specialist and niche health sites.

The FDA has cleared Wave Neuroscience's MeRT system, a personalized EEG-guided transcranial magnetic stimulation treatment for adult PTSD, based on a sham-controlled trial. The study reported a 52% reduction in symptoms and 68% remission rate among participants. Developed with Texas A&M researchers, it offers a non-medication adjunct option for patients unresponsive to existing therapies.

Why uncovered:Covered by ScienceDaily, PR Newswire, and medical device trade outlets, with limited pickup in major mainstream news organizations.

An observational study of over 17,000 UK Biobank participants found that meeting the standard 150 minutes per week of moderate-to-vigorous physical activity was associated with only an 8-9% lower risk of cardiovascular events. Achieving a greater than 30% risk reduction required roughly 560 to 610 minutes weekly, or three to four times current guidelines, with lower-fitness individuals needing slightly more activity for equivalent benefits. Researchers suggest future guidelines could distinguish minimum protection from optimal levels and personalize targets by fitness.

Why uncovered:Covered by health specialists, ScienceDaily, The Guardian and BMJ press materials, with limited broader mainstream pickup beyond initial May 2026 reports.

The World Health Organization reported on 4 August 2026 that Phase 1 trials of the first vaccines specific to the Bundibugyo Ebola strain have begun in the UK and Canada, while a post-exposure prophylaxis trial is underway in DR Congo’s Ituri province. The outbreak, the largest ever recorded in the country, has caused 3,748 confirmed cases and 1,657 deaths as of 1 August. No licensed vaccines or specific treatments currently exist for this strain.

Why uncovered:Covered by UN News, Reuters and specialist health outlets, with limited broader mainstream pickup beyond general outbreak reports and worker pay protests.

A peer-reviewed study from the Weizmann Institute of Science shows that sildenafil, the active ingredient in Viagra, can impair cancer cells' ability to metastasize by trapping cholesterol in lysosomes. Laboratory models and analysis of health records from millions of patients indicated reduced spread and improved survival, especially when combined with statins. Researchers call for clinical trials to explore potential therapeutic use.

Why uncovered:Covered by Weizmann, Cancer Research, Times of Israel, Healthline, Newsweek and science sites, with limited major international mainstream pickup.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorisation for Icotyde (icotrokinra), the first oral medicine targeting the interleukin-23 receptor for moderate-to-severe plaque psoriasis, and Susvimo (ranibizumab), a refillable ocular implant for neovascular age-related macular degeneration. Both positive opinions from the July 2026 meeting now go to the European Commission for final decisions. These recommendations expand treatment options for two common chronic conditions affecting quality of life and vision.

Why uncovered:Covered by EMA primary releases and specialist pharma outlets like The Pharma Letter and company statements, with limited mainstream media pickup.

The European Centre for Disease Prevention and Control (ECDC) has released new modular guidance on 20 July 2026 to strengthen routine surveillance of respiratory viruses including influenza, SARS-CoV-2 and RSV across the EU/EEA. The framework outlines action-oriented objectives, core and supplementary systems, and aims to enable earlier detection of changes in virus circulation to support timely public health measures. Additional modules are planned for later in 2026 and 2027.

Why uncovered:Covered by the official ECDC site and specialist EU monitoring outlet INSIGHT EU MONITORING, with no evident pickup in mainstream international media.

The European Centre for Disease Prevention and Control (ECDC) has issued a warning about an early start to the flu season in Europe, predicting a 'more severe' wave than usual. The agency is calling for immediate vaccination to mitigate the impact on public health. This alert highlights the urgency of preparedness amidst growing health concerns.

Why uncovered:The European Centre for Disease Prevention and Control (ECDC) warns of health risks from antimicrobial-resistant Salmonella and Campylobacter, signaling a growing public health threat. This is critical for public interest due to implications for food safety and healthcare systems.